MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2024 International Congress

    In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease

    C. Mahapatra (Mumbai, India)

    Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…
  • 2024 International Congress

    Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.

    B. Mukhammedaminov (Uzbekistan, Uzbekistan)

    Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…
  • 2023 International Congress

    Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease

    J. Jacobson, K. Ghoniem, A. Mullan, P. Turcano, C. Stang, E. Camerucci, C. Piat, J. Bower, R. Savica (Rochester, USA)

    Objective: To assess the usage frequency of dopamine agonists (DA), the prevalence of impulse control disorder (ICD) in patients with Early-onset Parkinson’s Disease (EOPD), and…
  • 2023 International Congress

    The role of depression in the development of Impulse Control Disorders in Parkinson´s Disease.

    M. Vales Montero, F. Ferre Navarrete, J. Conejo Galindo, P. Melgarejo Otálora, P. Andrés Camarón, J. Suárez Campayo, R. Reyes Marrero, JR. López-Trabada Gómez, MB. Díaz Rodríguez, F. Grandas (Madrid, Spain)

    Objective: We aimed to investigate whether depression is associated with a higher risk of developing impulse control disorders (ICD) in Parkinson´s disease (PD) patients and…
  • 2023 International Congress

    Novelty Seeking: A Narrative Review

    K. Paulk, L. Neilson (Portland, USA)

    Objective: To explore novelty seeking (NS) as a construct, in both its adaptive and maladaptive roles, in order to provide insight into the cognitive and…
  • 2023 International Congress

    Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

    V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

    Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…
  • 2023 International Congress

    REM sleep behavior disorder in Parkinson´s Disease: a risk factor for Impulse Control Disorders.

    M. Vales Montero, A. Contreras Chicote, B. Delacasa Fages, J. Pérez Sánchez, E. Luque Buzo, M. González Sánchez, F. Grandas (Madrid, Spain)

    Objective: We aimed to analyze de association between REM sleep behavior disorder (RBD) and impulse control disorders (ICD) in Parkinson´s disease (PD) patients and in…
  • 2023 International Congress

    The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

    CSC. Chuang (Changhua, Taiwan)

    Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…
  • 2023 International Congress

    Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial

    C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

    Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…
  • 2023 International Congress

    Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline

    B. Ugbedeojo, P. Adoyi, A. Abah, O. Onimisi, S. Musa, A. Omoniyi (Zaria, Nigeria)

    Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 16
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley